The worldwide marketplace for novel weight-loss medicine like Novo Nordisk A/S’s Ozempic and Wegovy is poised to achieve $100 billion by 2035 as sufferers begin to perceive the efficacy of the drugs.
That’s in keeping with BMO Capital Markets analyst Evan David Seigerman, who, in a be aware to purchasers late Thursday, additionally stated income for the drugs might attain as excessive as $70 billion within the US alone.
Wall Road’s urge for food for all issues weight-loss associated has been on the rise after a research of Novo Nordisk’s Wegovy confirmed the treatment lowered the dangers of coronary heart assaults and strokes. The research outcomes despatched shares of drugmaker Eli Lilly & Co. hovering, and it stays the best-performing pharmaceutical inventory thus far this yr within the S&P 500.
Seigerman sees Lilly as most poised to dominate the US market into the 2030s. He stated Lilly’s Mounjaro (tirzepatide) — already authorized for diabetes — will anchor weight-loss therapies into the late 2030s if the drug will get approval for weight problems by the top of the yr.
“We see change coming within the US payor and reimbursement atmosphere and data-driven, broad assist throughout medication, politics, regulation, and tradition for broad entry to weight problems therapeutics,” Seigerman wrote.
Morgan Stanley analysts projected in early August that the worldwide weight problems market will attain $77 billion in 2030, a rise from the beforehand estimated $54 billion.